Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 96
ABCS health sci ; 46: e021203, 09 fev. 2021. tab
Article in English | LILACS | ID: biblio-1147180


INTRODUCTION: The resistance of fungal species to drugs usually used in clinics is of great interest in the medical field. OBJECTIVE: To evaluate susceptibility and in vitro response of species of Trichophyton spp. to antifungal drugs of interest in clinical medicine. METHODS: 12 samples of clinical isolates from humans were used, nine of T. mentagrophytes and three of T. tonsurans. Susceptibility tests were performed according to the agar diffusion (AD) and broth microdilution (BM) methods. RESULTS: In the AD method, the species T. tonsurans presented a percentage of sensitivity of 33% in relation to amphotericin B and 66% to itraconazole, with 100% resistance to ketoconazole and fluconazole. T. mentagrophytes also showed 100% resistance to ketoconazole in this technique, with 11% sensitivity to ketoconazole, 22% to itraconazole and 22% of samples classified as sensitive dose dependent. In the MC method, the species T. tonsurans presented a sensitivity percentage of 66%, 55% and 33% in relation to ketoconazole, fluconazole and itraconazole, respectively. The T. mentagrophytes species presented sensitivity percentages of 11%, 11%, 33% and 55% for amphotericin B, itraconazole, ketoconazole and fluconazole, respectively. CONCLUSION: There was resistance in vitro of the species of T. mentagrophytes and T. tonsurans against the antifungal fluconazole and relative resistance against ketoconazole in the AD method. In BM, however, important percentages of sensitivity were observed for the two species analyzed in relation to the antifungals fluconazole and ketoconazole when compared to itraconazole and amphotericin B.

INTRODUÇÃO: A resistência de espécies fúngicas às drogas usualmente empregadas no meio clínico é motivo de grande interesse na área médica. OBJETIVO: Avaliar susceptibilidade e resposta in vitro de espécies de Trichophyton spp. a drogas antifúngicas de interesse em clínica médica. MÉTODOS: Foram utilizadas 12 amostras de isolados clínicos de humanos, sendo nove de T. mentagrophytes e três de T. tonsurans. Foram realizados testes de susceptibilidade segundo os métodos de difusão em ágar (DA) e microdiluição em caldo (MC). RESULTADOS: No método de DA, a espécie T. tonsurans apresentou percentual de sensibilidade de 33% em relação à anfotericina B e de 66% ao itraconazol, com 100% de resistência frente ao cetoconazol e ao fluconazol. A espécie T. mentagrophytes também apresentou 100% de resistência frente ao cetoconazol nesta técnica, com 11% de sensibilidade ao cetoconazol, 22% ao itraconazol e 22% das amostras classificadas como sensível dose dependente. No método de MC, a espécie T. tonsurans apresentou percentual de sensibilidade de 66%, 55% e 33% em relação ao cetoconazol, fluconazol e itraconazol, respectivamente. A espécie T. mentagrophytes apresentou percentuais de sensibilidade de 11%, 11%, 33% e 55% para anfotericina B, itraconazol, cetoconazol e fluconazol, respectivamente. CONCLUSÃO: Houve resistência in vitro das espécies do T. mentagrophytes e T. tonsurans frente ao antifúngico fluconazol e resistência relativa frente ao cetoconazol no método de DA. Na MC, no entanto, foram observados importantes percentuais de sensibilidade das duas espécies analisadas frente aos antifúngicos fluconazol e cetoconazol quando comparadas ao itraconazol e à anfotericina B.

Trichophyton/drug effects , Microbial Sensitivity Tests , Drug Resistance, Fungal , Disease Susceptibility/microbiology , Antifungal Agents/pharmacology , Tinea/microbiology , Tinea/drug therapy , Colony Count, Microbial , Fluconazole/pharmacology , Amphotericin B/pharmacology , Itraconazole/pharmacology , Ketoconazole/pharmacology
São Paulo med. j ; 138(1): 40-46, Jan.-Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1099387


BACKGROUND: Statins are used as cholesterol-lowering drugs and may also have direct antimicrobial effects. OBJECTIVE: To evaluate synergic interactions between simvastatin and both amphotericin B and fluconazole, against environmental strains of Cryptococcus neoformans isolated from captive birds' droppings. DESIGNAND SETTING: Experimental study conducted at Federal University of Piauí, Parnaíba, in collaboration with Federal University of Triângulo Mineiro, Uberaba, Brazil. METHODS: Statin susceptibility tests of Cryptococcus neoformans samples were performed as prescribed in standards. Interactions of simvastatin with amphotericin and fluconazole were evaluated using the checkerboard microdilution method. Presence of these interactions was quantitatively detected through determining the fractional inhibitory concentration index (FICI). RESULTS: Isolates of Cryptococcus neoformans were obtained from 30 of the 206 samples of dry bird excreta (14.5%) that were collected from pet shops and houses. Ten isolates were selected for susceptibility tests. All of them were susceptible to amphotericin and fluconazole. All presented minimum inhibitory concentration (MIC) > 128 µg/ml and, thus, were resistant in vitro to simvastatin. An in vitro synergic effect was shown through combined testing of amphotericin B and simvastatin, such that six isolates (60%) presented FICI < 0.500. Two isolates showed considerable reductions in MIC, from 1 µg/ml to 0.250 µg/ml. No synergic effect was observed through combining fluconazole and simvastatin. CONCLUSION: These results demonstrate that simvastatin should be considered to be a therapeutic alternative, capable of potentiating the action of amphotericin B. However, further studies are necessary to clarify the real effect of simvastatin as an antifungal agent.

Humans , Amphotericin B/pharmacology , Simvastatin/pharmacology , Cryptococcus neoformans , Brazil , Microbial Sensitivity Tests , Fluconazole , Prospective Studies , Drug Synergism , Antifungal Agents/pharmacology
Int. arch. otorhinolaryngol. (Impr.) ; 22(4): 400-403, Oct.-Dec. 2018. tab
Article in English | LILACS | ID: biblio-975604


Abstract Introduction Otomycosis is a common problem in otolaryngology practice. However, we usually encounter some difficulties in its treatment because many patients show resistance to antifungal agents, and present high recurrence rate. Objectives To determine the fungal pathogens that cause otomycosis as well as their susceptibility to the commonly used antifungal agents. Additionally, to discover the main reasons for antifungal resistance. Methods We conducted an experimental descriptive study on 122 patients clinically diagnosed with otomycosis from April 2016 to April 2017. Aural discharge specimens were collected for direct microscopic examination and fungal culture. In vitro antifungal susceptibility testing was performed against the commonly used antifungal drugs. We tested the isolated fungi for their enzymatic activity. Results Positive fungal infection was found in 102 samples. The most common fungal pathogens were Aspergillus and Candida species, with Aspergillus niger being the predominant isolate (51%). The antifungal susceptibility testing showed that mold isolates had the highest sensitivity to voriconazole (93.48%), while the highest resistance was to fluconazole (100%). For yeast, the highest sensitivity was to nystatin (88.24%), followed by amphotericin B (82.35%), and the highest resistance was to terbinafine (100%), followed by Itraconazole (94.12%). Filamentous fungi expressed a high enzymatic ability, making them more virulent. Conclusion The Aspergillus and Candida species are the most common fungal isolates in otomycosis. Voriconazole and Nystatin are the medications of choice for the treatment of otomycosis in our community. The high virulence of fungal pathogens is owed to their high enzymatic activity. Empirical use of antifungals should be discouraged.

Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Drug Resistance, Fungal , Otomycosis/microbiology , Fungi/isolation & purification , Antifungal Agents/pharmacology , Aspergillus/isolation & purification , Aspergillus niger/isolation & purification , Yeasts/isolation & purification , Candida/isolation & purification , Microbial Sensitivity Tests , Amphotericin B/pharmacology , Epidemiology, Descriptive , Clinical Trial , Itraconazole/pharmacology , Voriconazole/pharmacology , /pharmacology
Braz. j. biol ; 78(4): 673-678, Nov. 2018. tab, graf
Article in English | LILACS | ID: biblio-951612


Abstract Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting immunocompromised patients. However, severe side effects have limited the utility of this drug. The aim of this study was to evaluate the antifungal effect of the combination of amphotericin B with black tea or white tea and protective of citotoxic effect. The present study shows that white and black teas have additive effects with amphotericin B against some species Candida. In addition, the combination of white and black tea with amphotericin B may reduce the toxicity of amphotericin B to red blood cells. Our results suggest that white and black tea is a potential agent to combine with amphotericin for antifungal efficacy and to reduce the amphotericin dose to lessen side effects.

Resumo A anfotericina B é o tratamento de escolha para a maioria das infecções fúngicas sistémicas que afetam os doentes imunocomprometidos. No entanto, efeitos secundários graves têm limitado a utilidade desta droga. O objetivo deste estudo foi avaliar o efeito antifúngico da combinação de anfotericina B com chá preto ou chá branco, bem como o efeito citotóxico desta combinação sobre hemáceas. O presente estudo demonstra que o chá branco e preto de Camellia sinensis têm efeitos aditivos com anfotericina B contra algumas espécies de Candida sp. Além disso, a combinação de chá branco e preto com anfotericina B pode reduzir a toxicidade da anfotericina B em hemáceas. Nossos resultados sugerem que o chá branco e preto são agentes potenciais para associação com anfotericina B contribuindo para eficácia antifúngica, bem como redução de toxicidade.

Humans , Candida/drug effects , Amphotericin B/pharmacology , Camellia sinensis/adverse effects , Erythrocytes/drug effects , Antifungal Agents/pharmacology , Amphotericin B/adverse effects , Hemolysis/drug effects , Antifungal Agents/adverse effects
Rev. Soc. Bras. Med. Trop ; 51(3): 352-356, Apr.-June 2018. tab
Article in English | LILACS | ID: biblio-1041467


Abstract INTRODUCTION We describe the clinical and laboratorial features of oral candidiasis in 66 HIV-positive patients. METHODS: Polymerase chain reaction-based techniques were performed for differentiation of Candida spp. isolated from patients at a public teaching hospital in Midwest Brazil. RESULTS: Oral lesions, mainly pseudomembranous, were significantly related to higher levels of immunosuppression. Of 45 Candida isolates, 66.7% were C. albicans. Most of the isolates were susceptible to the antifungal drugs tested. CONCLUSIONS: Oral lesions were associated with higher immunosuppression levels. Lower susceptibility to antifungals by non-albicans isolates supports the importance of surveillance studies using susceptibility tests to aid in the treatment.

Humans , Male , Female , Adult , Young Adult , Candida/drug effects , Candidiasis, Oral/diagnosis , AIDS-Related Opportunistic Infections/diagnosis , Antifungal Agents/pharmacology , Brazil , Candida/isolation & purification , Candida/classification , Candidiasis, Oral/microbiology , Drug Resistance, Microbial , Microbial Sensitivity Tests , Fluconazole/pharmacology , Amphotericin B/pharmacology , Mycological Typing Techniques , AIDS-Related Opportunistic Infections/microbiology , Itraconazole/pharmacology , Middle Aged
Rev. Soc. Bras. Med. Trop ; 50(6): 843-847, Nov.-Dec. 2017. tab
Article in English | LILACS | ID: biblio-1041438


Abstract INTRODUCTION Incidence and antifungal susceptibility of Candida spp. from two teaching public hospitals are described. METHODS The minimum inhibitory concentrations of fluconazole, voriconazole, itraconazole, and amphotericin B were determined using Clinical Laboratory Standard Institute broth microdilution and genomic differentiation using PCR. RESULTS Of 221 Candida isolates, 50.2% were obtained from intensive care unit patients; 71.5% were recovered from urine and 9.1% from bloodstream samples. Candida parapsilosis sensu stricto was the most common candidemia agent. CONCLUSIONS We observed variations in Candida species distribution in hospitals in the same geographic region and documented the emergence of non-C. albicans species resistant to azoles.

Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Adolescent , Adult , Young Adult , Candida/drug effects , Candidiasis/microbiology , Antifungal Agents/pharmacology , Brazil , Candida/classification , Candida/genetics , Microbial Sensitivity Tests , Fluconazole/pharmacology , Amphotericin B/pharmacology , Itraconazole/pharmacology , Drug Resistance, Fungal , Voriconazole/pharmacology , Hospitals, Public , Middle Aged
Mem. Inst. Oswaldo Cruz ; 112(5): 376-381, May 2017. tab, graf
Article in English | LILACS | ID: biblio-841795


BACKGROUND Sporothrix brasiliensis is the most virulent sporotrichosis agent. This species usually responds to antifungal drugs, but therapeutic failure can occur in some patients. Antifungal susceptibility tests have been performed on this species, but no clinical breakpoints (CBPs) are available. In this situation, minimal inhibitory concentration (MIC) distributions and epidemiological cutoff values (ECVs) support the detection of identification of resistant strains. OBJECTIVES To study the MIC distributions of five antifungal drugs against S. brasiliensis and to propose tentative ECVs. METHODS MICs of amphotericin B (AMB), itraconazole (ITR), ketoconazole (KET), posaconazole (POS), and terbinafine (TRB) against 335 S. brasiliensis strains were determined by the Clinical and Laboratory Standards Institute broth microdilution method. FINDINGS The proposed ECV, in µg/mL, for AMB, ITR, KET, POS, and TRB were 4.0, 2.0, 1.0, 2.0, and 0.25, respectively. Percentages of wild-type strains in our population for the above antifungal drugs were 98.48, 95.22, 95.33, 100, and 97.67%, respectively. MAIN CONCLUSIONS These ECVs will be useful to detect strains with resistance, to define CBPs, and to elaborate specific therapeutic guidelines for S. brasiliensis. Rational use of antifungals is strongly recommended to avoid the emergence of resistant strains and ensure the therapeutic effectiveness of sporotrichosis.

Humans , Animals , Cats , Sporothrix/drug effects , Triazoles/pharmacology , Amphotericin B/pharmacology , Itraconazole/pharmacology , Ketoconazole/pharmacology , Antifungal Agents/pharmacology , Naphthalenes/pharmacology , Drug Resistance , Cats , Anti-Infective Agents
Mem. Inst. Oswaldo Cruz ; 112(2): 155-159, Feb. 2017. tab, graf
Article in English | LILACS | ID: biblio-1040566


BACKGROUND Gene reporter-fluorescent cells have emerged as alternative method for drug screening. OBJECTIVE Achievement of constitutive expression of fluorescent protein GFP by Leishmania braziliensis as alternative method for drug screening. METHODS L. braziliensis-GFP was generated using Leishmania tarentolae pLEXSY-egfp for constitutive expression of GFP. Fluorescent cells were selected and subjected to standardisation tests of anti-promastigote and anti-intracellular amastigote assays. FINDINGS Our results showed that L. braziliensis-GFP method is faster and more sensitive than Allamar Blue-resazurin. MAIN CONCLUSION Transfected parasites maintained stable fluorescence after successive in vitro passages and pLEXSY system can be used to achieve non-L. tarentolae fluorescent cells.

Animals , Leishmania braziliensis/drug effects , Amphotericin B/pharmacology , Green Fluorescent Proteins/pharmacology , Drug Evaluation, Preclinical/methods , Antiprotozoal Agents/pharmacology , Time Factors , Microscopy, Fluorescence
Journal of Gorgan University of Medical Sciences. 2017; 19 (2): 59-64
in Persian | IMEMR | ID: emr-189299


Background and Objective: Candida albicans is the normal flora of the body as opportunistic fungi. It causes candidiasis in immunocompromised condition. This study was done to drug susceptibility testing of Candida albicans isolated from patients against Amphotericin B and Ketoconazole

Methods: In this descriptive - analytic study, drug susceptibility of 30 Candida albicans isolated from patients admitted to Tehran hospitals, Iran was tested against Amphotericin B and Ketoconazole by micro dilution method in accordance with CLSI M27-A2 guideline and disk diffusion method in accordance with CLSI M44-S2 guideline. Standard isolate Candida albicans PTCC [5027] and Candida krusei PTCC [5295] were used for quality control

Results: The minimum and maximum MIC against Amphotrericin B was 0.0625 micro[-1] and 4 micro[-1], respectively. The minimum and maximum MIC against Ketoconazole was 0.5 micro g/ml[-1] and 32 micro g/ml[-1], respectively. The minimum and maximum zone diameter was 6 and 28 mm for both drugs. The results of drug susceptibility testing by two methods did not show significant differences. 25 isolates [83.3%] against ketoconazole and 2 isolates [6.7%] against Amphotericin B were resistant

Conclusion: Amphotericin B administration seems better choice in candidiasis treatment in comparision with Ketoconazole

Humans , Amphotericin B/pharmacology , Ketoconazole/pharmacology , Microbial Sensitivity Tests , Disk Diffusion Antimicrobial Tests
Braz. j. biol ; 76(4): 1029-1034, Oct.-Dec. 2016. tab, graf
Article in English | LILACS | ID: biblio-828088


Abstract Amphotericin B is a fungicidal substance that is treatment of choice for most systemic fungal infections affecting as cryptococcosis the immunocompromised patients. However, severe side effects have limited the utility of this drug. The aim of this study was to evaluate the antifungal effect of the combination of amphotericin B with quercetin or rutin and as a protective of citotoxic effect. The antifungal activity to amphotericin B, quercetin and rutin alone and in combination was determined in Candida sp and Cryptococcus neoformans strains. Cytotoxicity test on erythrocytes was performed by spectrophotometric absorbance of hemoglobin. The amphotericin B MIC was reduced when used in combination with quercetin or rutin to C. neoformans ATCC strain and reduced when combined with rutin to a clinical isolate of C. neoformans. In addition, the combination of quercetin with amphotericin B may reduce the toxicity of amphotericin B to red blood cells. Our results suggest that quercetin and rutin are potential agents to combine with amphotericin B in order to reduce the amphotericin dose to lessen side effects and improve antifungal efficacy.

Resumo A anfotericina B é uma substância fungicida e é o tratamento de escolha para a maioria das infecções fúngicas sistêmicas que afetam os pacientes imunocomprometidos, como a criptococose. No entanto, as severas reações adversas têm limitado a utilização desta droga. O objetivo deste estudo foi avaliar o efeito antifúngico e o potencial efeito protetor de citotoxicidade da combinação de anfotericina B com quercetina ou rutina. A atividade antifúngica de anfotericina B, quercetina e rutina, isoladamente e em combinação foi determinada em cepas de Candida sp e Cryptococcus neoformans. O teste de citotoxicidade em eritrócitos foi realizado por espectrofotometria, através da determinação da absorbância da hemoglobina. A concentração inibitória mínima da anfotericina B foi reduzida quando utilizada em combinação com a quercetina e rutina em C. neoformans ATCC e reduzida quando combinados com rutina em um isolado clínico de C. neoformans. Além disso, a combinação de quercetina com anfotericina B pode reduzir a toxicidade da droga em eritrócitos. Os resultados sugerem que quercetina e rutina são potenciais agentes para combinação com anfotericina B, a fim de reduzir a dose de anfotericina, diminuindo os efeitos colaterais e melhorando sua eficácia antifúngica.

Quercetin/pharmacology , Rutin/pharmacology , Candida/drug effects , Amphotericin B/pharmacology , Cryptococcus neoformans/drug effects , Antifungal Agents/pharmacology , Candida/growth & development , Microbial Sensitivity Tests , Cryptococcus neoformans/growth & development
Braz. j. infect. dis ; 20(6): 539-545, Nov.-Dec. 2016. tab
Article in English | LILACS | ID: biblio-828164


ABSTRACT The antifungal activity of tacrolimus in combination with antifungal agents against different fungal species has been previously reported. Here we report the in vitro interactions between tacrolimus and amphotericin B, fluconazole, itraconazole, and caspofungin against 30 clinical isolates of both fluconazole-susceptible and fluconazole-resistant Trichosporon asahii. For these analyses, we used the broth microdilution method based on the M27-A3 technique and checkerboard microdilution method. Tacrolimus showed no activity against T. asahii strains (minimal inhibitory concentrations, MICs > 64.0 µg mL−1). However, a larger synergistic interaction was observed by the combinations tacrolimus + amphotericin B (96.67%) and tacrolimus + caspofungin (73.33%) against fluconazole-susceptible isolates. Combinations with azole antifungal agents resulted in low rates of synergism for this group (fluconazole + tacrolimus = 40% and itraconazole + tacrolimus = 10%). Antagonistic interactions were not observed. For the fluconazole-resistant T. asahii group, all tested combinations showed indifferent interactions. The synergism showed against fluconazole-susceptible T. asahii isolates suggests that the potential antifungal activity of tacrolimus deserves in vivo experimental investigation, notably, the combination of tacrolimus with amphotericin B or caspofungin.

Humans , Trichosporon/drug effects , Tacrolimus/pharmacology , Calcineurin Inhibitors/pharmacology , Antifungal Agents/pharmacology , Microbial Sensitivity Tests , Fluconazole/pharmacology , Amphotericin B/pharmacology , Itraconazole/pharmacology , Drug Interactions , Drug Synergism , Echinocandins/pharmacology , Lipopeptides/pharmacology , Caspofungin
Braz. j. infect. dis ; 19(5): 459-465, tab, graf
Article in English | LILACS | ID: lil-764506


ABSTRACTThe antifungal activity of some statins against different fungal species has been reported. Thus, at the first moment, the in vitro antifungal activity of simvastatin, atorvastatin and pravastatin was tested againstCandida spp. and Cryptococcus spp. Then, in a second approach, considering that the best results were obtained for simvastatin, this drug was evaluated in combination with antifungal drugs against planktonic growth and tested against biofilms ofCandida spp. and Cryptococcus spp. Drug susceptibility testing was performed using the microdilution broth method, as described by the Clinical and Laboratory Standards Institute. The interaction between simvastatin and antifungals against planktonic cells was analyzed by calculating the fractional inhibitory concentration index. Regarding biofilm susceptibility, simvastatin was tested against growing biofilm and mature biofilm of one strain of each tested yeast species. Simvastatin showed inhibitory effect against Candida spp. andCryptococcus spp. with minimum inhibitory concentration values ranging from 15.6 to 1000 mg L-1 and from 62.5 to 1000 mg L-1, respectively. The combination of simvastatin with itraconazole and fluconazole showed synergism against Candidaspp. and Cryptococcus spp., while the combination of simvastatin with amphotericin B was synergistic only againstCryptococcus spp. Concerning the biofilm assays, simvastatin was able to inhibit both growing biofilm and mature biofilm ofCandida spp. and Cryptococcus spp. The present study showed that simvastatin inhibits planktonic cells and biofilms ofCandida and Cryptococcus species.

Animals , Antifungal Agents/pharmacology , Biofilms/drug effects , Candida/drug effects , Cryptococcus/drug effects , Simvastatin/pharmacology , Amphotericin B/pharmacology , Biofilms/growth & development , Candida/classification , Candida/physiology , Cryptococcus/classification , Cryptococcus/physiology , Drug Synergism , Fluconazole/pharmacology , Itraconazole/pharmacology , Microbial Sensitivity Tests
J. appl. oral sci ; 23(4): 412-418, July-Aug. 2015. tab
Article in English | LILACS, BBO | ID: lil-759358


AbstractPost-antifungal effect (PAFE) of Candida and its production of hemolysin are determinants of candidal pathogenicity. Candida albicans is the foremost aetiological agent of oral candidosis, which can be treated with polyene, azole, and echinocandin antifungals. However, once administered, the intraoral concentrations of these drugs tend to be subtherapeutic and transient due to the diluent effect of saliva and cleansing effect of the oral musculature. Hence, intra-orally, Candidamay undergo a brief exposure to antifungal drugs.Objective Therefore, the PAFE and hemolysin production of oral C. albicans isolates following brief exposure to sublethal concentrations of the foregoing antifungals were evaluated.Material and Methods A total of 50 C. albicans oral isolates obtained from smokers, diabetics, asthmatics using steroid inhalers, partial denture wearers and healthy individuals were exposed to sublethal concentrations of nystatin, amphotericin B, caspofungin, ketoconazole and fluconazole for 60 min. Thereafter, the drugs were removed and the PAFE and hemolysin production were determined by previously described turbidometric and plate assays, respectively.Results Nystatin, amphotericin B, caspofungin and ketoconazole induced mean PAFE (hours) of 2.2, 2.18, 2.2 and 0.62, respectively. Fluconazole failed to produce a PAFE. Hemolysin production of these isolates was suppressed with a percentage reduction of 12.27, 13.47, 13.33, 8.53 and 4.93 following exposure to nystatin, amphotericin B, caspofungin, ketoconazole and fluconazole, respectively.Conclusions Brief exposure to sublethal concentrations of antifungal drugs appears to exert an antifungal effect by interfering with the growth as well as hemolysin production of C. albicans.

Humans , Antifungal Agents/pharmacology , Candida albicans/drug effects , Candida albicans/isolation & purification , Drug Resistance, Fungal/drug effects , Hemolysin Proteins/drug effects , Amphotericin B/pharmacology , Candida albicans/metabolism , Case-Control Studies , Colony Count, Microbial , Echinocandins/pharmacology , Fluconazole/pharmacology , Hemolysin Proteins/metabolism , Ketoconazole/pharmacology , Microbial Sensitivity Tests , Nystatin/pharmacology , Statistics, Nonparametric , Time Factors
Rev. Inst. Med. Trop. Säo Paulo ; 57(3): 185-191, May-Jun/2015. tab, graf
Article in English | LILACS | ID: lil-752603


Infections by Candida species are a high-impact problem in public health due to their wide incidence in hospitalized patients. The goal of this study was to evaluate frequency, susceptibility to antifungals, and genetic polymorphism of Candida species isolated from clinical specimens of hospitalized patients. The Candida isolates included in this study were obtained from blood cultures, abdominal fluids, and central venous catheters (CVC) of hospitalized patients at the Clinical Hospital of the Federal University of Uberlândia during the period of July 2010 - June 2011. Susceptibility tests were conducted by the broth microdilution method. The RAPD-PCR tests used employed initiator oligonucleotides OPA09, OPB11, and OPE06. Of the 63 Candida isolates, 18 (28.5%) were C. albicans, 20 (31.7%) were C. parapsilosis complex species, 14 (22.2%) C. tropicalis, four (6.4%) C. glabrata, four (6.4%) C. krusei, two (3.3%) C. kefyr, and one (1.6%) C. lusitaniae. In vitro resistance to amphotericin B was observed in 12.7% of isolates. In vitro resistance to azoles was not detected, except for C. krusei. The two primers, OPA09 and OPB11, were able to distinguish different species. Isolates of C. albicans and C. parapsilosis complex species presented six and five clusters, respectively, with the OPA09 marker by RAPD-PCR, showing the genetic variability of the isolates of those species. It was concluded that members of the C. parapsilosis complex were the most frequent species found, and most isolates were susceptible to the antifungals amphotericin B, flucozanole, and itraconazole. High genetic polymorphisms were observed for isolates of C. albicans and C. parapsilosis complex species, mainly with the OPA09 marker.

As infecções causadas por espécies de Candida são problema de grande impacto para a saúde pública, devido à alta incidência em pacientes hospitalizados e como causa de mortalidade. O presente estudo teve como objetivo avaliar a frequência de Candida spp. isoladas de pacientes hospitalizados, assim como a sensibilidade aos antifúngicos e o polimorfismo genético por RAPD-PCR. Os microrganismos incluíram isolados de hemocultura, líquido abdominal e ponta de cateter venoso central de pacientes internados no Hospital de Clínicas da Universidade Federal de Uberlândia, região do Triângulo Mineiro, Minas Gerais, Brasil, no período de julho de 2010-junho de 2011. Os testes de sensibilidade aos antifúngicos foram realizados por microdiluição em caldo e na análise por RAPD-PCR foram utilizados os oligonucleotídeos OPA09, OPB11, e OPE06. Dos 63 isolados, 18 (28,5%) foram C. albicans, 20 (31,7%) C. parapsilosis, 14 (22,2%) C. tropicalis, quatro (6,4%) C. glabrata, quatro (6,4%) C. krusei, dois (3,3%) C. kefyr, e um (1,6%) C. lusitaniae. Resistência in-vitro à anfotericina B foi observada em 12,7% dos isolados. Não foi observada resistência in-vitro aos azólicos, exceto para os isolados de C. krusei. Os oligonucleotídeos OPA09 e OPB11 possibilitaram distinguir diferentes espécies. Isolados de C. albicans apresentaram seis clusters e o complexo C. parapsilosis, cinco clusters, com o iniciador OPA09, por RAPD-PCR, mostrando a variabilidade genética daquelas espécies. Conclui-se que o complexo C. parapsilosis foi a espécie mais frequente, e a maioria dos isolados foi sensível in vitro aos antifúngicos testados. Alto polimorfismo genético foi observado para os isolados de C. albicans e complexo C. parapsilosis, principalmente com o oligonucleotídeo OPA09.

Aged, 80 and over , Female , Humans , Infant , Infant, Newborn , Male , Antifungal Agents/pharmacology , Candida/classification , Candida/drug effects , DNA, Fungal , Amphotericin B/pharmacology , Brazil , Candida/genetics , Candida/isolation & purification , Drug Resistance, Fungal , Fluconazole/pharmacology , Itraconazole/pharmacology , Mycological Typing Techniques , Microbial Sensitivity Tests/methods , Polymerase Chain Reaction , Random Amplified Polymorphic DNA Technique , Tertiary Healthcare
The Korean Journal of Parasitology ; : 385-394, 2015.
Article in English | WPRIM | ID: wpr-50466


Leishmaniasis is a worldwide uncontrolled parasitic disease due to the lack of effective drug and vaccine. To speed up effective drug development, we need powerful methods to rapidly assess drug effectiveness against the intracellular form of Leishmania in high throughput assays. Reporter gene technology has proven to be an excellent tool for drug screening in vitro. The effects of reporter proteins on parasite infectivity should be identified both in vitro and in vivo. In this research, we initially compared the infectivity rate of recombinant Leishmania major expressing stably enhanced green fluorescent protein (EGFP) alone or EGFP-luciferase (EGFP-LUC) with the wild-type strain. Next, we evaluated the sensitivity of these parasites to amphotericin B (AmB) as a standard drug in 2 parasitic phases, promastigote and amastigote. This comparison was made by MTT and nitric oxide (NO) assay and by quantifying the specific signals derived from reporter genes like EGFP intensity and luciferase activity. To study the amastigote form, both B10R and THP-1 macrophage cell lines were infected in the stationary phase and were exposed to AmB at different time points. Our results clearly revealed that the 3 parasite lines had similar in vitro infectivity rates with comparable parasite-induced levels of NO following interferon-gamma/lipopolysaccharide induction. Based on our results we proposed the more reporter gene, the faster and more sensitive evaluation of the drug efficiency.

Animals , Female , Humans , Mice , Amphotericin B/pharmacology , Antiprotozoal Agents/pharmacology , Drug Evaluation, Preclinical/instrumentation , Gene Expression , Genes, Reporter , Green Fluorescent Proteins/genetics , Leishmania major/drug effects , Leishmaniasis, Cutaneous/parasitology , Luciferases/genetics
Annals of Laboratory Medicine ; : 602-610, 2015.
Article in English | WPRIM | ID: wpr-76934


BACKGROUND: We investigated the species distribution and amphotericin B (AMB) susceptibility of Korean clinical Aspergillus isolates by using two Etests and the CLSI broth microdilution method. METHODS: A total of 136 Aspergillus isolates obtained from 11 university hospitals were identified by sequencing the internal transcribed spacer (ITS) and beta-tubulin genomic regions. Minimal inhibitory concentrations (MICs) of AMB were determined in Etests using Mueller-Hinton agar (Etest-MH) and RPMI agar (Etest-RPG), and categorical agreement with the CLSI method was assessed by using epidemiological cutoff values. RESULTS: ITS sequencing identified the following six Aspergillus species complexes: Aspergillus fumigatus (42.6% of the isolates), A. niger (23.5%), A. flavus (17.6%), A. terreus (11.0%), A. versicolor (4.4%), and A. ustus (0.7%). Cryptic species identifiable by beta-tubulin sequencing accounted for 25.7% (35/136) of the isolates. Of all 136 isolates, 36 (26.5%) had AMB MICs of > or =2 microg/mL by the CLSI method. The categorical agreement of Etest-RPG with the CLSI method was 98% for the A. fumigatus, A. niger, and A. versicolor complexes, 87% for the A. terreus complex, and 37.5% for the A. flavus complex. That of Etest-MH was < or =75% for the A. niger, A. flavus, A. terreus, and A. versicolor complexes but was higher for the A. fumigatus complex (98.3%). CONCLUSIONS: Aspergillus species other than A. fumigatus constitute about 60% of clinical Aspergillus isolates, and reduced AMB susceptibility is common among clinical isolates of Aspergillus in Korea. Molecular identification and AMB susceptibility testing by Etest-RPG may be useful for characterizing Aspergillus isolates of clinical relevance.

Humans , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Aspergillus/drug effects , DNA, Fungal/chemistry , Hospitals , Microbial Sensitivity Tests , Mycoses/diagnosis , Republic of Korea , Sequence Analysis, DNA , Tubulin/genetics
Biomédica (Bogotá) ; 34(4): 589-597, oct.-dic. 2014. ilus, graf
Article in English | LILACS | ID: lil-730943


Introduction: Photodynamic therapy (PDT) using 5-aminolevulinic acid-induced protoporphyrin IX (ALA-PpIX) constitutes an interesting alternative for cutaneous leishmaniasis treatment. Objective: To evaluate the production of PpIXbased on the administration of ALA and MAL and the effect of ALA-PDTat cellular level on non-infected and infected THP-1 cells using Leishmania ( Viannia ) panamensis or Leishmania ( Leishmania ) infantum (syn Leishmania chagasi ) parasites. Materials and methods: Protoporphyrin IX (PpIX) production and mitochondrial colocalization were evaluated by confocal microscopy. Cell toxicities were evaluated after treatment with the compounds, followed by light irradiation (597-752 nm) at 2.5 J/cm 2 fluency using a colorimetric MTT assay for THP-1 cells and a standard microscopic analysis of parasites. Results were expressed as compound concentration activity against 50% of cells or parasites (CC 50 or IC 50 ). Results: ALA or MAL induced an endogenous PpIX with a red fluorescence localized mainly in the mitochondria inside human cells. ALA and MAL-PDT induced a similar range of toxicities on THP-1 cells (CC 50 0.16±0.01mM and 0.33±0.019 mM, respectively) without any apparent inhibition of intracellular parasites in the infected cells as compared to untreated controls. Exogenous PpIX-PDT was toxic to THP-1 cells (CC 50 0.00032±0.00002 mM), L. (L.) infantum (IC 50 0.003±0.0001 mM) and L. (V.) panamensis (IC 50 0.024±0.0001 mM) promastigotes. Conclusions: Despite the effectiveness of exogenous PpIX on promastigotes and the production of PpIX by human infected cells, treatment with ALA or MAL before irradiation was unable to completely destroy L. (L.) infantum or L. (V.) panamensis intracellular amastigotes.

Introducción. El tratamiento fotodinámico con ácido 5-aminolevulínico como inductor de la protoporfirina IX (ALA-PpIX) constituye una alternativa interesante en el tratamiento de la leishmaniasis cutánea. Objetivo. Evaluar la producción de protoporfirina IX (PpIX) a partir de la administración de ALA o MAL y el efecto de la PDT con ALA a nivel celular en células THP-1 no infectadas e infectadas con Leishmania ( Viannia ) panamensis o Leishmania ( Leishmania ) infantum (syn. Leishmania chagasi ). Materiales y métodos. La producción de protoporfirina IX y su ‘colocalización´ mitocondrial se evaluaron mediante microscopía ‘confocal´. Se evaluó la toxicidad celular después del tratamiento con los compuestos y la aplicación de irradiación de luz (597-752 nm) en una fluencia de 2,5 J/cm 2 mediante el empleo de la prueba colorimétrica con metil-tiazol-tetrazolio (MTT) en las células, y de métodos microscópicos estándar en los parásitos. Los resultados se expresaron como la concentración del compuesto activo en el 50 % de las células o parásitos (CC 50 o CI 50 ). Resultados. El ácido aminolevulínico o el metil-5-aminolevulinato indujeron la protoporfirina IX endógena en células humanas, y se observó fluorescencia de color rojo en las mitocondrias. La actividad del ácido aminolevulínico y del metil-5-aminolevulinato utilizados con terapia fotodinámica fue similar en las células THP-1 (CC 50 0,16±0,01 mM y 0,33±0,019 mM, respectivamente) y, aparentemente, no inhibió los parásitos en las células infectadas, en comparación con los controles. El tratamiento exógeno con protoporfirina IX y terapia fotodinámica fue tóxico para las células THP-1 (CC 50 0,00032 ±0,00002 mM) y para los promastigotes de L. (L .) infantum (IC 50 0,003±0,0001 mM) y L. ( V .) panamensis (CI 50 0,024±0,0001 mM). Conclusiones. A pesar de la ‘fotoactividad´ del tratamiento con protoporfirina IX en promastigotes y de su producción después del tratamiento con ácido aminolevulínico y metil-5-aminolevulinato en las células infectadas con Leishmania , no se observó daño en los amastigotes presentes en las células de L. ( L .) infantum o L . ( V .) panamensis .

Humans , Aminolevulinic Acid/analogs & derivatives , Aminolevulinic Acid/pharmacology , Leishmania guyanensis/drug effects , Leishmania infantum/drug effects , Monocytes/drug effects , Photochemotherapy , Photosensitizing Agents/pharmacology , Protoporphyrins/analysis , Subcellular Fractions/drug effects , Aminolevulinic Acid/radiation effects , Amphotericin B/pharmacology , Cell Line, Tumor , Colorimetry , Leukemia, Monocytic, Acute/pathology , Lysosomes/chemistry , Microscopy, Fluorescence , Mitochondria/chemistry , Monocytes/parasitology , Monocytes/ultrastructure , Photosensitizing Agents/radiation effects , Species Specificity , Subcellular Fractions/chemistry
Rev. argent. microbiol ; 46(2): 111-118, jun. 2014. tab, mapas
Article in Spanish | LILACS | ID: lil-734573


El objetivo de este trabajo fue evaluar los resultados de sensibilidad a los antifúngicos de diversas especies de Candida utilizando el sistema semiautomatizado Vitek 2 (tarjetas AST-YSO1; bioMérieux), y compararlos con los obtenidos por el método de referencia del Clinical and Laboratory Standards Institute (CLSI), la microdilución en caldo (Documento M27-A3, 2008). La concordancia esencial fue > 90 %, excepto en el caso de Candida glabrata frente al voriconazol (VCZ) y de Candida krusei frente al fluconazol (FCZ). La concordancia global por categoría (variación no mayor que 2 diluciones, sin discriminar por especie) fue > 90 % cuando se evaluó el FCZ, y 89,5 % a las 24 h y 80,7 % a las 48 h con el VCZ. El tiempo promedio para obtener los resultados fue de 15,5 h. Los errores menores (sensible o resistente por un método y dosis dependiente por el otro) para FCZ fueron de 7,8 % a las 24 h y 6,1 % a las 48 h; para VCZ, 10,5 % a las 24 h y 19,3 % a las 48 h. Solo se detectó 1 error muy mayor (resistente por el método de referencia y sensible por Vitek 2) con Candida parapsilosis frente a FCZ a las 48 h. No se observaron errores mayores (sensibles por el método de referencia y resistentes por Vitek 2). Con respecto a la anfotericina B, solo 3 cepas presentaron una CIM = 2 ?g/ml. El sistema Vitek 2 detectó correctamente el valor de CIM para diversas especies de Candida y presentó una excelente concordancia con el método de referencia propuesto por el CLSI.

The aim of this investigation was to evaluate the results of antifungal susceptibility for various Candida species using the Vitek 2 semi-automated system (AST-YSO1 cards, bioMérieux), and to compare them with those obtained by the CLSI (Clinical and Laboratory Standards Institute) broth microdilution reference method (Document M27-A3,2008). The essential agreement (EA) was > 90%, except for Candida glabrata against voriconazole (VCZ); and for Candida krusei against fluconazole (FCZ). The overall categorical agreement (CA) was > 90% when FCZ was evaluated and 89.5% at 24 h and 80.7% at 48 h for VCZ. The average time for obtaining results was 15.5 h. Minor errors were 7.8% at 24 h and 6.1% at 48 h for FCZ, and 10.5% at 24 h and 19.3% at 48 h for VCZ. There was only one very major error for FCZ against Candida parapsilosis and no major errors were observed. For amphotericin B, only three isolates showed MICs = 2 ?g/ml. The Vitek 2 system detected the MIC value for various Candida species and showed excellent agreement with the reference method proposed by the CLSI.

Humans , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Candida/drug effects , Fluconazole/pharmacology , Pyrimidines/pharmacology , Triazoles/pharmacology , Microbial Sensitivity Tests , Mycology/methods , Voriconazole
Journal of Gorgan University of Medical Sciences. 2014; 15 (4): 66-71
in English, Persian | IMEMR | ID: emr-139742


Aspergillosis is the most current causative agent of exogenous fungal nosocomial infection. This study was done to evaluate the drug susceptibility of Aspergillus flavus and A.fumigatus to itraconazole and amphotericin B. This Laboratory study was done on 25 Aspergillus fumigatus and 25 Aspergillus flavus species isolated from transplant's patients. Drug susceptibility test was done according to NCCLS M38-P document. Fungal suspensions of mentioned fungi were supplied with ranges 0.5-5x10[4] by spectrophotometer at 530 nm. Serial dilutions of drugs were supplied from 0.03125 to 16 microg/ml and MICs determined following 48h incubation at 35C. Obtained MICs ranges for Aspergillus fumigatus and Aspergillus flavus were 1-4 microg/ml and 0.5-4 micro g/ml for itraconazole, respectively while MICs ranges against Aspergillus fumigatus and Aspergillus flavus were 0.5-2 micro g/ml and 0.25-2 microg/ml for amphotericin B, respectively. Amphotericin B MICs were significantly lower than itraconazole [P<0.05]. Aspergillus flavus and A.fumigatus were susceptible to amphotericin B and itraconazole

Humans , Amphotericin B/pharmacology , Amphotericin B , Itraconazole/pharmacology , Itraconazole , Aspergillus fumigatus/drug effects , Drug Resistance, Microbial , Antifungal Agents/pharmacology , Microbial Sensitivity Tests , Aspergillus flavus/drug effects
Journal of Gorgan University of Medical Sciences. 2014; 15 (4): 53-58
in English, Persian | IMEMR | ID: emr-139744


Ultraviolet [UV] radiation is an important disinfectant. Fungal infections with resistant isolates in patients culminate in recurrence of disease even with worse condition. This study was done to evaluate the efficacy of ultraviolet radiation on drug susceptibility of Candida Spp. To itraconazole, fluconazole and amphotericin B. This laboratory study was done on 12 Candida spp. isolated from patients according to NCCLS M27- A method. Samples were suspended with sterile saline and optical density was read by spectrophotometer at the wavelength of 530 nm. Serial dilutions [0.0313-16 microg/ml] and [0.0313-128 microg/ml] were supplied for itraconazole, amphotericin and fluconazole, respectively. MICs were determined after 48h incubation at 35°C. Following UV radiation for 1, 2, 5, 10, 60, 90 and 120 seconds MICs were determined, subsequently. The highest MIC pre UV radiation was [>128 microg/ml] for fluconazole. After UV radiation, MICs were steadily decreased for all mentioned drugs while after 10 sec, MICs of itraconazole and amphotericin B were >0.0313 microg/ml. Secondary MICs significantly decreased with respect to MICs obtained in pre UV radiation [P<0.05]. UV radiation reduces MICs of Candida spp. to itraconazole, fluconazole, amphotericin B

Candida/drug effects , Ultraviolet Rays , Itraconazole/pharmacology , Fluconazole/pharmacology , Amphotericin B/pharmacology , Microbial Sensitivity Tests